OBJECTIVE: To compare biochemical recurrence (BCR)-free survival and predictors of BCR in intermediate-risk (IR) and high-risk (HR) patients undergoing robotic-assisted laparoscopic prostatectomy (RALP) vs open radical prostatectomy (ORP).
MATERIALS AND METHODS: We conducted a retrospective study on 1336 men with D'Amico IR or HR prostate cancer who underwent RALP or ORP between 2003 and 2009. Exclusion criteria were use of neoadjuvant therapy, < 6 months of follow-up, and insufficient clinicopathologic data. We compared demographic, clinical, and pathologic variables between groups. Kaplan-Meier analysis was performed to compare the 5-year BCR-free survival between groups. Multivariate models were developed to determine whether surgical approach influences BCR.
RESULTS: A total of 979 IR and HR patients (237 ORP and 742 RALP patients) met inclusion criteria. Median follow-up was shorter for RALP (43 vs 63 months; P < .001). ORP patients had a higher median prostate-specific antigen level (7.9 vs 6.7 ng/mL; P < .002), significantly more Gleason sum 8-10 tumors, and more adverse pathologic features overall. There was no difference in positive surgical margins between groups. Pathologic features including extraprostatic extension, seminal vesicle involvement, lymph node involvement, pathologic Gleason sum, and positive surgical margin were significant independent predictors of BCR in multivariate analysis. Surgical approach (RALP vs ORP) did not predict BCR when controlling for other known predictors of BCR.
CONCLUSION: Among IR and HR prostate cancer patients, the oncologic outcomes are similar between RALP and ORP. Not surprisingly, adverse pathologic features are harbingers of BCR.
Written by:
Ritch CR, You C, May AT, Herrell SD, Clark PE, Penson DF, Chang SS, Cookson MS, Smith JA Jr, Barocas DA. Are you the author?
Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN; Department of Urology, University of Oklahoma Medical Center, Oklahoma City, OK.
Reference: Urology. 2014 Apr 17. pii: S0090-4295(14)00182-4.
doi: 10.1016/j.urology.2014.02.023
PubMed Abstract
PMID: 24746665
UroToday.com Prostate Cancer Section
